Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens.

Autor: Ahmadzadeh A; Health research institute, Research Center of Thalassemia & Hemoglobinopathy,Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Yekaninejad MS; Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran., Jalili MH; Department of internal medicine, school of medicine, Tehran University of medical sciences, Tehran, Iran., Bahadoram M; Department of internal medicine, school of medicine, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran., Efazat M; Department of internal medicine, school of medicine, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran., Seghatoleslami M; Health research institute, Research Center of Thalassemia & Hemoglobinopathy,Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Yazdi F; Department of internal medicine, Ganjavian hospital, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran., Mahdipour M; Department of surgery, Arvand hospital, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran., Valizadeh A; Department of Anatomy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Saki N; Health research institute, Research Center of Thalassemia & Hemoglobinopathy,Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Jazyk: angličtina
Zdroj: International journal of hematology-oncology and stem cell research [Int J Hematol Oncol Stem Cell Res] 2014; Vol. 8 (2), pp. 21-6.
Abstrakt: In this study we surveyed the average survival time of the treated Hodgkin's lymphoma patients and also the side effects and malignancies occurring secondary to the treatment. This is a retrospective study of patients referring to Ahwaz's Shafa hospital in a period of 10 years diagnosed with Hodgkin's lymphoma without any age restriction. After gathering all their data, we calculated their survival rate and the chance for a relapse and the secondary malignancies. 389 patients were included in the study with an average age of 27.5 years old and they had received only chemotherapy regimens. 87.9% of them had been treated by ABVD and 12.1 % by Stanford V regimen. 23.1% of them experienced a relapse and 13.1% of all patients, passed away during the study. Secondary malignancies were observed in 11 cases. An overall mean survival time of 295.31 months was resulted. The secondary malignancies after treating Hodgkin's lymphoma patients are different between chemotherapy regimens and chemotherapy - radiotherapy.
Databáze: MEDLINE
Externí odkaz: